CL2018002763A1 - Moléculas de unión a bcma y métodos de uso de las mismas. - Google Patents
Moléculas de unión a bcma y métodos de uso de las mismas.Info
- Publication number
- CL2018002763A1 CL2018002763A1 CL2018002763A CL2018002763A CL2018002763A1 CL 2018002763 A1 CL2018002763 A1 CL 2018002763A1 CL 2018002763 A CL2018002763 A CL 2018002763A CL 2018002763 A CL2018002763 A CL 2018002763A CL 2018002763 A1 CL2018002763 A1 CL 2018002763A1
- Authority
- CL
- Chile
- Prior art keywords
- polinucleotides
- methods
- binding molecules
- bcma binding
- polypeptides
- Prior art date
Links
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
LA INVENCIÓN PROPORCIONA ANTICUERPOS, FRAGMENTOS DE UNIÓN A ANTÍGENO DE ELLOS, RECEPTORES DE ANTÍGENOS QUIMÉRICOS (CAR), Y RECEPTORES DE CÉLULAS T MODIFICADOS GENÉTICAMENTE, POLINUCLEÓTIDOS QUE CODIFICAN LOS MISMOS, Y CÉLULAS IN VITRO QUE COMPRENDEN LOS MISMOS. LOS POLINUCLEÓTIDOS, POLIPÉPTIDOS Y CÉLULAS IN VITRO DESCRITOS EN LA PRESENTE SE PUEDEN USAR EN UNA TERAPIA DE CÉLULAS T CAR MODIFICADAS GENÉTICAMENTE PARA EL TRATAMIENTO DE UN PACIENTE QUE SUFRE DE CÁNCER. EN UNA FORMA DE REALIZACIÓN, LOS POLINUCLEÓTIDOS, POLIPÉPTIDOS Y CÉLULAS IN VITRO DESCRITOS EN LA PRESENTE SE PUEDEN USAR PARA EL TRATAMIENTO DEL MIELOMA MÚLTIPLE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662317334P | 2016-04-01 | 2016-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018002763A1 true CL2018002763A1 (es) | 2019-04-26 |
Family
ID=59959188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018002763A CL2018002763A1 (es) | 2016-04-01 | 2018-09-27 | Moléculas de unión a bcma y métodos de uso de las mismas. |
Country Status (24)
Country | Link |
---|---|
US (3) | US10689450B2 (es) |
EP (1) | EP3436036A4 (es) |
JP (2) | JP7366543B2 (es) |
KR (3) | KR102397674B1 (es) |
CN (2) | CN116425876A (es) |
AR (1) | AR108067A1 (es) |
AU (2) | AU2017240150C1 (es) |
BR (1) | BR112018070159A2 (es) |
CA (1) | CA3019135A1 (es) |
CL (1) | CL2018002763A1 (es) |
CO (1) | CO2018010475A2 (es) |
CR (1) | CR20180462A (es) |
CU (1) | CU20180120A7 (es) |
DO (1) | DOP2018000212A (es) |
EA (1) | EA201891966A1 (es) |
EC (1) | ECSP18073836A (es) |
IL (1) | IL261942A (es) |
NZ (1) | NZ746700A (es) |
PE (1) | PE20190120A1 (es) |
PH (1) | PH12018550164A1 (es) |
SG (2) | SG11201808403SA (es) |
TW (4) | TWI707950B (es) |
WO (1) | WO2017173349A1 (es) |
ZA (1) | ZA201806962B (es) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170233484A1 (en) | 2016-02-17 | 2017-08-17 | Seattle Genetics, Inc. | Bcma antibodies and use of same to treat cancer and immunological disorders |
CR20210084A (es) | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
BR112018070073A2 (pt) | 2016-04-01 | 2019-02-12 | Kite Pharma, Inc. | receptores de antígeno quimérico e célula t e métodos de uso |
EP3600447A4 (en) * | 2017-03-20 | 2020-12-30 | Baylor College of Medicine | TRANSGENIC C-MPL TO INTRODUCE LIGAND-DEPENDENT CO-STIMULATION AND CYTOKINE SIGNALS INTO GENETICALLY MODIFIED CELLS BY TCR |
US11897953B2 (en) | 2017-06-14 | 2024-02-13 | The Broad Institute, Inc. | Compositions and methods targeting complement component 3 for inhibiting tumor growth |
KR20200047660A (ko) | 2017-09-01 | 2020-05-07 | 다나-파버 캔서 인스티튜트 인크. | 암의 치료를 위한 bcma 및 taci 항원에 특이적인 면역원성 펩타이드 |
WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
US20210363260A1 (en) | 2017-11-13 | 2021-11-25 | The Broad Institute, Inc. | Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway |
WO2019099707A1 (en) | 2017-11-16 | 2019-05-23 | Kite Pharma, Inc | Modified chimeric antigen receptors and methods of use |
EP3757133A4 (en) | 2018-02-11 | 2021-12-01 | Jiangsu Hengrui Medicine Co., Ltd. | ISOLATED CHIMERIC ANTIGEN RECEPTOR, THIS MODIFIED T-CELL CONTAINED AND USES |
EP3752531A1 (en) * | 2018-02-14 | 2020-12-23 | Kite Pharma, Inc. | Anti-idiotypic antibodies directed to the antigen-binding portion of an bcma-binding molecule |
EA202091974A1 (ru) * | 2018-02-21 | 2020-12-08 | Селджин Корпорейшн | Связывающие bcma антитела и их применение |
JP2021521841A (ja) * | 2018-04-27 | 2021-08-30 | クリスパー セラピューティクス アーゲー | 形質細胞枯渇のための抗bcma car−t細胞 |
WO2019232542A2 (en) | 2018-06-01 | 2019-12-05 | Massachusetts Institute Of Technology | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients |
CN110818802B (zh) * | 2018-08-08 | 2022-02-08 | 华夏英泰(北京)生物技术有限公司 | 一种嵌合t细胞受体star及其应用 |
WO2020072700A1 (en) | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
WO2020081730A2 (en) | 2018-10-16 | 2020-04-23 | Massachusetts Institute Of Technology | Methods and compositions for modulating microenvironment |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020131586A2 (en) | 2018-12-17 | 2020-06-25 | The Broad Institute, Inc. | Methods for identifying neoantigens |
EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
US11739156B2 (en) | 2019-01-06 | 2023-08-29 | The Broad Institute, Inc. Massachusetts Institute of Technology | Methods and compositions for overcoming immunosuppression |
AU2020231218A1 (en) * | 2019-03-06 | 2021-09-16 | Dana-Farber Cancer Institute, Inc. | T cell receptors specific to B-cell maturation antigen for treatment of cancer |
US20220154282A1 (en) | 2019-03-12 | 2022-05-19 | The Broad Institute, Inc. | Detection means, compositions and methods for modulating synovial sarcoma cells |
US20220142948A1 (en) | 2019-03-18 | 2022-05-12 | The Broad Institute, Inc. | Compositions and methods for modulating metabolic regulators of t cell pathogenicity |
WO2020236967A1 (en) | 2019-05-20 | 2020-11-26 | The Broad Institute, Inc. | Random crispr-cas deletion mutant |
AU2020298572A1 (en) | 2019-07-02 | 2021-11-18 | Fred Hutchinson Cancer Center | Recombinant Ad35 vectors and related gene therapy improvements |
WO2021030627A1 (en) | 2019-08-13 | 2021-02-18 | The General Hospital Corporation | Methods for predicting outcomes of checkpoint inhibition and treatment thereof |
US20220298501A1 (en) | 2019-08-30 | 2022-09-22 | The Broad Institute, Inc. | Crispr-associated mu transposase systems |
US11793787B2 (en) | 2019-10-07 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis |
US11844800B2 (en) | 2019-10-30 | 2023-12-19 | Massachusetts Institute Of Technology | Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia |
CN113045657B (zh) * | 2019-12-26 | 2022-06-07 | 杭州济元基因科技有限公司 | 一种人源化抗人bcma单克隆抗体及其car-t细胞 |
CN111234020B (zh) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | 一种bcma结合蛋白及其制备方法和应用 |
WO2021231959A1 (en) * | 2020-05-15 | 2021-11-18 | Precision Biosciences, Inc. | Methods for immunotherapy |
GB202100754D0 (en) | 2021-01-20 | 2021-03-03 | Coding Bio Ltd | Methods for high throughput screening of chimeric antigen receptors |
TW202246333A (zh) * | 2021-01-20 | 2022-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合bcma和cd3的抗原結合分子及其醫藥用途 |
US20240067955A1 (en) | 2021-01-20 | 2024-02-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
CN116745325A (zh) * | 2021-08-16 | 2023-09-12 | 上海优替济生生物医药有限公司 | Bcma靶向抗体、嵌合抗原受体及其应用 |
GB202116514D0 (en) | 2021-11-16 | 2021-12-29 | Coding Bio Ltd | Computational methods for the design and optimisation of chimeric antigen receptors (cars) |
US20240059782A1 (en) * | 2022-03-01 | 2024-02-22 | Agilent Technologies, Inc. | Anti-human b cell maturation antigen (bcma) antibodies and their use in immunohistochemistry (ihc) |
WO2024077256A1 (en) | 2022-10-07 | 2024-04-11 | The General Hospital Corporation | Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
JP3262724B2 (ja) | 1996-12-25 | 2002-03-04 | 福岡丸本株式会社 | 栽培装置 |
US6892139B2 (en) | 1999-01-29 | 2005-05-10 | The Regents Of The University Of California | Determining the functions and interactions of proteins by comparative analysis |
US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
AU4328801A (en) | 2000-02-24 | 2001-09-03 | Xcyte Therapies Inc | Simultaneous stimulation and concentration of cells |
CN1671416B (zh) | 2001-07-12 | 2013-01-02 | 杰斐逊·富特 | 超人源化抗体 |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP1636265A2 (en) | 2003-06-25 | 2006-03-22 | Crucell Holland B.V. | Binding molecules for the treatment of myeloid cell malignancies |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
WO2007137300A2 (en) | 2006-05-23 | 2007-11-29 | Bellicum Pharmaceuticals, Inc. | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
EP2352756B1 (en) * | 2008-11-24 | 2012-09-19 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | High affinity t cell receptor and use thereof |
PT2406284T (pt) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anticorpos anti-bcma |
WO2011041093A1 (en) | 2009-10-01 | 2011-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer |
US20120227134A1 (en) | 2009-11-17 | 2012-09-06 | Basf Plant Science Company Gmbh | Plants with Increased Yield |
EP2566887A1 (en) | 2010-05-05 | 2013-03-13 | Addex Pharma SA | Chimeric receptors and methods for identifying agents exhibiting an activity on type 1 single pass transmembrane receptors |
US9089520B2 (en) | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
WO2012033885A1 (en) | 2010-09-08 | 2012-03-15 | Baylor College Of Medicine | Immunotherapy of cancer using genetically engineered gd2-specific t cells |
DK3012268T3 (en) | 2010-09-08 | 2018-02-19 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
NZ612512A (en) | 2010-12-09 | 2015-03-27 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
MX2013008376A (es) | 2011-01-18 | 2013-08-12 | Univ Pennsylvania | Composiciones y metodos para el tratamiento de cancer. |
US9024028B2 (en) | 2011-01-26 | 2015-05-05 | Ariad Pharmaceuticals, Inc. | Methods and compositions for the synthesis of multimerizing agents |
RU2688185C2 (ru) | 2011-03-23 | 2019-05-21 | Фред Хатчинсон Кэнсер Рисерч Сентер | Способ и композиции для клеточной иммунотерапии |
PL3415531T3 (pl) * | 2011-05-27 | 2024-02-26 | Glaxo Group Limited | Białka wiążące antygen |
EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
CA2848410A1 (en) | 2011-09-16 | 2013-03-21 | The Trustees Of The University Of Pennsylvania | Rna engineered t cells for the treatment of cancer |
TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
DE102012204596A1 (de) | 2012-03-22 | 2013-09-26 | Ford Global Technologies, Llc | Verfahren und Vorrichtung zum Regeln der Geschwindigkeit eines Kraftfahrzeugs |
EP2828290B1 (en) | 2012-03-23 | 2018-08-15 | The United States of America, represented by the Secretary, Department of Health and Human Services | Anti-mesothelin chimeric antigen receptors |
EP3505176A1 (en) | 2012-04-02 | 2019-07-03 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
EP3689383A1 (en) * | 2012-04-11 | 2020-08-05 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
US9163090B2 (en) | 2012-05-07 | 2015-10-20 | Cellerant Therapeutics, Inc. | Antibodies specific for CLL-1 |
CN104395344B (zh) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US9598489B2 (en) | 2012-10-05 | 2017-03-21 | The Trustees Of The Univeristy Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
TW201425336A (zh) * | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
US10077315B2 (en) * | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
CA3115383A1 (en) * | 2013-02-06 | 2014-08-14 | Celgene Corporation | Modified t lymphocytes having improved specificity |
KR20210147101A (ko) | 2013-02-15 | 2021-12-06 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
WO2014186469A2 (en) | 2013-05-14 | 2014-11-20 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
CA2930587A1 (en) | 2013-11-25 | 2015-05-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors to control hiv infection |
US20160376375A1 (en) | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
US20150344844A1 (en) | 2014-02-04 | 2015-12-03 | Marc Better | Methods for producing autologous t cells useful to treat b cell malignancies and other cancers and compositions thereof |
US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
EP3119423B1 (en) | 2014-03-15 | 2022-12-14 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
EP3131927B8 (en) | 2014-04-14 | 2020-12-23 | Cellectis | Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
KR20170037625A (ko) | 2014-07-21 | 2017-04-04 | 노파르티스 아게 | Cll-1 키메라 항원 수용체를 사용한 암의 치료 |
AU2015292590B2 (en) * | 2014-07-24 | 2020-01-16 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
AR101846A1 (es) | 2014-09-12 | 2017-01-18 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados |
IL292650B2 (en) * | 2014-09-19 | 2024-04-01 | Hope City | IL13RA2-targeted chimeric antigen receptor T cells |
KR20170083534A (ko) | 2014-09-19 | 2017-07-18 | 리제너론 파마슈티칼스 인코포레이티드 | 키메라 항원 수용체 |
CN107429253B (zh) | 2014-12-05 | 2021-11-05 | 希望之城公司 | Cs1靶向性嵌合抗原受体修饰的t细胞 |
CN113698497A (zh) | 2014-12-05 | 2021-11-26 | 纪念斯隆-凯特琳癌症中心 | 靶向b-细胞成熟抗原的嵌合抗原受体及其用途 |
LT3628687T (lt) | 2014-12-12 | 2021-11-10 | 2Seventy Bio, Inc. | Chimeriniai bcma antigeno receptoriai |
CN105445991A (zh) | 2014-12-26 | 2016-03-30 | 深圳市华星光电技术有限公司 | 彩色滤光片的制作方法 |
MY196625A (en) | 2015-04-13 | 2023-04-23 | Pfizer | Therapeutic Antibodies and Their Uses |
US10294304B2 (en) | 2015-04-13 | 2019-05-21 | Pfizer Inc. | Chimeric antigen receptors targeting B-cell maturation antigen |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
MA44507A (fr) | 2016-04-01 | 2019-02-06 | Amgen Inc | Récepteurs chimères de flt3 et leurs procédés d'utilisation |
CR20210084A (es) | 2016-04-01 | 2021-03-26 | Amgen Inc | Receptores quiméricos y métodos de uso de los mismos (divisional 2018-0480) |
AU2017240150C1 (en) | 2016-04-01 | 2022-10-27 | Kite Pharma, Inc. | BCMA binding molecules and methods of use thereof |
BR112018070073A2 (pt) | 2016-04-01 | 2019-02-12 | Kite Pharma, Inc. | receptores de antígeno quimérico e célula t e métodos de uso |
-
2017
- 2017-03-31 AU AU2017240150A patent/AU2017240150C1/en active Active
- 2017-03-31 NZ NZ746700A patent/NZ746700A/en unknown
- 2017-03-31 TW TW106111226A patent/TWI707950B/zh active
- 2017-03-31 TW TW109115604A patent/TWI761831B/zh active
- 2017-03-31 WO PCT/US2017/025516 patent/WO2017173349A1/en active Application Filing
- 2017-03-31 KR KR1020187031269A patent/KR102397674B1/ko active IP Right Grant
- 2017-03-31 TW TW110147901A patent/TWI795133B/zh active
- 2017-03-31 SG SG11201808403SA patent/SG11201808403SA/en unknown
- 2017-03-31 CU CU2018000120A patent/CU20180120A7/es unknown
- 2017-03-31 KR KR1020237012515A patent/KR102591930B1/ko active IP Right Grant
- 2017-03-31 PE PE2018001932A patent/PE20190120A1/es not_active Application Discontinuation
- 2017-03-31 CN CN202310108490.6A patent/CN116425876A/zh active Pending
- 2017-03-31 CA CA3019135A patent/CA3019135A1/en active Pending
- 2017-03-31 KR KR1020227015639A patent/KR102522622B1/ko active IP Right Grant
- 2017-03-31 CN CN201780030900.2A patent/CN109414455B/zh active Active
- 2017-03-31 US US15/476,309 patent/US10689450B2/en active Active
- 2017-03-31 EP EP17776833.0A patent/EP3436036A4/en not_active Withdrawn
- 2017-03-31 CR CR20180462A patent/CR20180462A/es unknown
- 2017-03-31 AR ARP170100822A patent/AR108067A1/es unknown
- 2017-03-31 SG SG10201912515XA patent/SG10201912515XA/en unknown
- 2017-03-31 BR BR112018070159-9A patent/BR112018070159A2/pt unknown
- 2017-03-31 JP JP2018550679A patent/JP7366543B2/ja active Active
- 2017-03-31 EA EA201891966A patent/EA201891966A1/ru unknown
- 2017-03-31 TW TW112105413A patent/TW202323273A/zh unknown
-
2018
- 2018-09-26 IL IL261942A patent/IL261942A/en unknown
- 2018-09-27 PH PH12018550164A patent/PH12018550164A1/en unknown
- 2018-09-27 CL CL2018002763A patent/CL2018002763A1/es unknown
- 2018-09-28 CO CONC2018/0010475A patent/CO2018010475A2/es unknown
- 2018-10-01 EC ECSENADI201873836A patent/ECSP18073836A/es unknown
- 2018-10-01 DO DO2018000212A patent/DOP2018000212A/es unknown
- 2018-10-18 ZA ZA2018/06962A patent/ZA201806962B/en unknown
-
2019
- 2019-09-12 US US16/569,341 patent/US11505613B2/en active Active
-
2022
- 2022-02-10 JP JP2022019896A patent/JP2022065073A/ja active Pending
- 2022-02-23 AU AU2022201243A patent/AU2022201243A1/en not_active Abandoned
- 2022-11-14 US US18/055,188 patent/US20230146195A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018002763A1 (es) | Moléculas de unión a bcma y métodos de uso de las mismas. | |
CO2018004315A2 (es) | Conjugados de 2-amino-pirrolo [3,2] pirimidina con anticuerpos anti-her-2 | |
SV2018005634A (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos | |
CY1121907T1 (el) | Συζευγματα antidll3-antiσωmatoς-pbd και χρησεις αυτων | |
CL2022003264A1 (es) | Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros | |
CY1121723T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CL2019000259A1 (es) | Anticuerpos, antimiostatina, polipéptidos que contienen regiones fc variantes y métodos de uso.(divisional solicitud 201701584) | |
CY1119799T1 (el) | Συνδυασμος αντισωματων anti-kir και αντισωματων anti-pd-1 για αγωγη καρκινου | |
CL2017000954A1 (es) | Moléculas de unión a antígeno biespecificas activadoras de células t | |
CL2017000836A1 (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer. | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
CO2018013298A2 (es) | Anticuerpos anti-gitr y sus usos. | |
BR112017019914A2 (pt) | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b | |
CO2018011195A2 (es) | Composiciones que comprenden una coformulación de anticuerpos anti-pd-l1 y anti-ctla-4 | |
DOP2015000108A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasas | |
BR112017013176A2 (pt) | receptores de antígenos quiméricos e métodos para usá-los | |
BR112016030740A2 (pt) | diacorpos heterodiméricos biespecíficos e seus usos | |
BR112016024957A2 (pt) | métodos aperfeiçoados para fabricação de terapias celulares adotivas | |
AR108468A1 (es) | POLIPÉPTIDOS DE FUSIÓN CD40L-Fc Y MÉTODOS DE USO DE LOS MISMOS | |
CL2018001722A1 (es) | Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506) | |
CL2019001671A1 (es) | Anticuerpos específicos para fcrn (divisional solicitud 201601147) | |
CL2021003422A1 (es) | Anticuerpos anti il-13ra2 y usos de los mismos (divisional 201902323). | |
GT201500267A (es) | Anticuerpos anti-cd52 | |
CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso |